c50e900405fbdd1247c34af7b7d6ce48 pmc_33014837.pdf 52e49506ade79d30dfbbb18b122b38c985232695 pmc_33014837.pdf 4444c4df71762233d2b39dc2017d36b7bd725bab2b39e42e875e62ddd9b19b71 pmc_33014837.pdf Title: Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-Small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents Subject: Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. Keywords: immune-related adverse events, immunotherapy, advanced NSCLC, corticosteroids, efficacy Author: Margarita Majem Creator: LaTeX with hyperref package + hypdvips Producer: dvips + MiKTeX GPL Ghostscript 9.0 CreationDate: Mon Sep 7 10:04:24 2020 CEST ModDate: Mon Sep 7 11:42:16 2020 CEST Custom Metadata: no Metadata Stream: yes Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 11 Encrypted: no Page size: 595.26 x 779.52 pts Page rot: 0 File size: 557270 bytes Optimized: no PDF version: 1.6 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- CHTYZU+HelveticaNeueLTStd-Lt Type 1C Custom yes yes no 36 0 HEQYRG+HelveticaNeueLTStd-BdIt Type 1C WinAnsi yes yes no 49 0 PLJIVA+HelveticaNeueLTStd-LtIt Type 1C Custom yes yes no 51 0 YBIBRD+HelveticaNeueLTStd-MdIt Type 1C WinAnsi yes yes no 56 0 OBAZBH+RMTMI Type 1C WinAnsi yes yes no 58 0 UCVRXE+MTSY Type 1C Custom yes yes no 60 0 XTLRTA+HelveticaNeueLTStd-Bd Type 1C Custom yes yes no 31 0 ESCAIU+MinionPro-Regular Type 1C Custom yes yes no 68 0 RUEZTD+MinionPro-Bold Type 1C Custom yes yes no 97 0 AYJXIO+MTSYB Type 1C Custom yes yes no 99 0 XUXRYW+MinionPro-It Type 1C WinAnsi yes yes no 92 0 GBAUGV+RMTMIB Type 1C WinAnsi yes yes no 144 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2024-10-02 04:18:22 CEST RepresentationInformation: pmc_33014837.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2023-03-31 11:43:26 CEST Size: 557270 Format: PDF Version: 1.6 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 258 FreeObjects: 16 IncrementalUpdates: 0 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: true CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseOutlines Language: en Outlines: Item: Title: Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-Small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents Destination: ariclecounter.1 Children: Item: Title: Introduction Destination: section*.2 Item: Title: Materials and Methods Destination: section*.3 Children: Item: Title: Statistical Analysis Destination: section*.4 Item: Title: Results Destination: section*.5 Children: Item: Title: Patient Characteristics Destination: section*.6 Item: Title: Anti-PD-(L)1 Blockade Treatment and irAEs Characteristics Destination: section*.7 Item: Title: Association Between irAEs and Treatment Outcomes Destination: section*.8 Item: Title: Association Between the Use of Corticosteroids and Efficacy Destination: section*.9 Item: Title: Association Between the Use of Antibiotics and Efficacy Destination: section*.10 Item: Title: Multivariable Analysis Destination: section*.11 Item: Title: Discussion Destination: section*.12 Item: Title: Data Availability Statement Destination: section*.13 Item: Title: Ethics Statement Destination: section*.14 Item: Title: Author Contributions Destination: section*.15 Item: Title: Funding Destination: section*.16 Item: Title: Acknowledgments Destination: section*.17 Item: Title: Supplementary Material Destination: section*.18 Item: Title: References Destination: section*.19 Info: Title: Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-Small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents Author: Margarita Majem Subject: Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. Keywords: immune-related adverse events, immunotherapy, advanced NSCLC, corticosteroids, efficacy Creator: LaTeX with hyperref package + hypdvips Producer: dvips + MiKTeX GPL Ghostscript 9.0 CreationDate: Mon Sep 07 10:34:24 CEST 2020 ModDate: Mon Sep 07 12:12:16 CEST 2020 ID: 0xf6d535b9742db0c3075d400400e4dc0a, 0x605d4fad71ef9142b827d373c0c69f07 Filters: FilterPipeline: FlateDecode FilterPipeline: DCTDecode Images: Image: NisoImageMetadata: FormatName: image/png ImageWidth: 279 ImageHeight: 279 ColorSpace: RGB BitsPerSample: 8 BitsPerSampleUnit: integer Filter: FlateDecode Image: NisoImageMetadata: FormatName: image/jpg CompressionScheme: JPEG ImageWidth: 992 ImageHeight: 1449 ColorSpace: RGB BitsPerSample: 8 BitsPerSampleUnit: integer Interpolate: true Image: NisoImageMetadata: FormatName: image/jpg CompressionScheme: JPEG ImageWidth: 992 ImageHeight: 2296 ColorSpace: RGB BitsPerSample: 8 BitsPerSampleUnit: integer Interpolate: true Fonts: Type1: Font: BaseFont: GBAUGV+RMTMIB FontSubset: true FirstChar: 60 LastChar: 60 FontDescriptor: FontName: GBAUGV+RMTMIB Flags: Nonsymbolic, AllCap FontBBox: 0, 0, 682, 455 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: HEQYRG+HelveticaNeueLTStd-BdIt FontSubset: true FirstChar: 42 LastChar: 121 FontDescriptor: FontName: HEQYRG+HelveticaNeueLTStd-BdIt Flags: Nonsymbolic FontBBox: -63, -182, 717, 731 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: RUEZTD+MinionPro-Bold FontSubset: true FirstChar: 3 LastChar: 117 FontDescriptor: FontName: RUEZTD+MinionPro-Bold Flags: Symbolic FontBBox: 0, -244, 687, 703 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: PLJIVA+HelveticaNeueLTStd-LtIt FontSubset: true FirstChar: 0 LastChar: 250 FontDescriptor: FontName: PLJIVA+HelveticaNeueLTStd-LtIt Flags: Symbolic FontBBox: -137, -206, 978, 729 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: AYJXIO+MTSYB FontSubset: true FirstChar: 21 LastChar: 68 FontDescriptor: FontName: AYJXIO+MTSYB Flags: Symbolic FontBBox: 0, -133, 724, 551 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: CHTYZU+HelveticaNeueLTStd-Lt FontSubset: true FirstChar: 0 LastChar: 150 FontDescriptor: FontName: CHTYZU+HelveticaNeueLTStd-Lt Flags: Serif, Symbolic FontBBox: -30, -214, 904, 786 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: ESCAIU+MinionPro-Regular FontSubset: true FirstChar: 2 LastChar: 252 FontDescriptor: FontName: ESCAIU+MinionPro-Regular Flags: Symbolic FontBBox: -26, -257, 956, 713 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: YBIBRD+HelveticaNeueLTStd-MdIt FontSubset: true FirstChar: 42 LastChar: 237 FontDescriptor: FontName: YBIBRD+HelveticaNeueLTStd-MdIt Flags: Symbolic FontBBox: -133, -205, 891, 731 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: OBAZBH+RMTMI FontSubset: true FirstChar: 60 LastChar: 62 FontDescriptor: FontName: OBAZBH+RMTMI Flags: Nonsymbolic, AllCap FontBBox: 0, 0, 683, 455 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: UCVRXE+MTSY FontSubset: true FirstChar: 20 LastChar: 68 FontDescriptor: FontName: UCVRXE+MTSY Flags: Symbolic FontBBox: 0, -133, 724, 551 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true Font: BaseFont: XUXRYW+MinionPro-It FontSubset: true FirstChar: 40 LastChar: 169 FontDescriptor: FontName: XUXRYW+MinionPro-It Flags: Symbolic FontBBox: -142, -257, 903, 712 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: XTLRTA+HelveticaNeueLTStd-Bd FontSubset: true FirstChar: 0 LastChar: 150 FontDescriptor: FontName: XTLRTA+HelveticaNeueLTStd-Bd Flags: Serif, Symbolic FontBBox: -9, -214, 925, 786 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true XMP: 2020-09-07T13:34:24+05:30 LaTeX with hyperref package + hypdvips 2020-09-07T15:12:16+05:30 2020-09-07T15:12:16+05:30 application/pdf Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. Margarita Majem Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-Small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents immune-related adverse events immunotherapy advanced NSCLC corticosteroids efficacy immune-related adverse events, immunotherapy, advanced NSCLC, corticosteroids, efficacy dvips + MiKTeX GPL Ghostscript 9.0 uuid:6a10b72d-45f4-42b2-b176-5204af39e254 uuid:f0553432-07cc-4b86-9417-55dd1750279d Pages: Page: Label: 1 Annotations: Annotation: Subtype: Link Rect: 43, 719, 140, 755 Annotation: Subtype: Link Rect: 474, 736, 551, 744 Annotation: Subtype: Link Rect: 456, 728, 498, 736 Annotation: Subtype: Link Rect: 498, 728, 533, 736 Annotation: Subtype: Link Rect: 533, 728, 551, 736 Annotation: Subtype: Link Rect: 457, 720, 551, 728 Annotation: Subtype: Link Rect: 521, 678, 551, 709 Annotation: Subtype: Link Rect: 43, 30, 109, 38 Annotation: Subtype: Link Rect: 112, 30, 172, 38 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Annotation: Subtype: Link Rect: 87, 447, 160, 457 Annotation: Subtype: Link Rect: 91, 309, 160, 318 Annotation: Subtype: Link Rect: 79, 70, 160, 77 Annotation: Subtype: Link Rect: 176, 487, 551, 646 Page: Label: 2 Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 120, 544, 127, 555 Destination: External Annotation: Subtype: Link Rect: 129, 544, 135, 555 Destination: External Annotation: Subtype: Link Rect: 47, 475, 53, 486 Destination: External Annotation: Subtype: Link Rect: 56, 475, 63, 486 Destination: External Annotation: Subtype: Link Rect: 128, 440, 135, 452 Destination: External Annotation: Subtype: Link Rect: 138, 440, 149, 452 Destination: External Annotation: Subtype: Link Rect: 252, 360, 263, 372 Destination: External Annotation: Subtype: Link Rect: 256, 337, 267, 349 Destination: External Annotation: Subtype: Link Rect: 270, 337, 281, 349 Destination: External Annotation: Subtype: Link Rect: 157, 269, 168, 280 Destination: External Annotation: Subtype: Link Rect: 171, 269, 182, 280 Destination: External Annotation: Subtype: Link Rect: 165, 223, 176, 234 Destination: External Annotation: Subtype: Link Rect: 179, 223, 190, 234 Destination: External Annotation: Subtype: Link Rect: 388, 496, 399, 507 Destination: External Annotation: Subtype: Link Rect: 339, 393, 350, 404 Destination: External Annotation: Subtype: Link Rect: 43, 28, 109, 37 Annotation: Subtype: Link Rect: 112, 28, 172, 36 Annotation: Subtype: Link Rect: 420, 28, 551, 37 Page: Label: 3 Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 208, 582, 219, 594 Destination: External Annotation: Subtype: Link Rect: 223, 582, 234, 594 Destination: External Annotation: Subtype: Link Rect: 469, 525, 499, 533 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 4 Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 188, 227, 219, 236 Destination: External Annotation: Subtype: Link Rect: 138, 158, 168, 167 Destination: External Annotation: Subtype: Link Rect: 442, 351, 495, 361 Destination: External Annotation: Subtype: Link Rect: 391, 90, 426, 98 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 5 Sequence: 5 Annotations: Annotation: Subtype: Link Rect: 365, 135, 405, 145 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 6 Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 251, 204, 281, 213 Destination: External Annotation: Subtype: Link Rect: 229, 133, 270, 144 Destination: External Annotation: Subtype: Link Rect: 493, 580, 546, 590 Destination: External Annotation: Subtype: Link Rect: 339, 124, 375, 132 Destination: External Annotation: Subtype: Link Rect: 394, 124, 435, 132 Destination: External Annotation: Subtype: Link Rect: 362, 78, 398, 87 Destination: External Annotation: Subtype: Link Rect: 418, 78, 459, 87 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 7 Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 215, 169, 252, 178 Destination: External Annotation: Subtype: Link Rect: 429, 80, 440, 91 Destination: External Annotation: Subtype: Link Rect: 443, 80, 454, 91 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 8 Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 307, 239, 313, 250 Destination: External Annotation: Subtype: Link Rect: 316, 239, 322, 250 Destination: External Annotation: Subtype: Link Rect: 458, 135, 469, 147 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 9 Sequence: 9 Annotations: Annotation: Subtype: Link Rect: 82, 605, 93, 617 Destination: External Annotation: Subtype: Link Rect: 95, 605, 106, 617 Destination: External Annotation: Subtype: Link Rect: 259, 502, 270, 514 Destination: External Annotation: Subtype: Link Rect: 274, 502, 285, 514 Destination: External Annotation: Subtype: Link Rect: 47, 353, 58, 365 Destination: External Annotation: Subtype: Link Rect: 144, 124, 155, 135 Destination: External Annotation: Subtype: Link Rect: 404, 536, 415, 548 Destination: External Annotation: Subtype: Link Rect: 472, 353, 484, 365 Destination: External Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Page: Label: 10 Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 552, 427, 303, 452 Annotation: Subtype: Link Rect: 170, 357, 263, 366 Annotation: Subtype: Link Rect: 196, 338, 276, 347 Annotation: Subtype: Link Rect: 195, 310, 274, 319 Annotation: Subtype: Link Rect: 199, 282, 277, 290 Annotation: Subtype: Link Rect: 81, 234, 180, 243 Annotation: Subtype: Link Rect: 108, 187, 209, 196 Annotation: Subtype: Link Rect: 292, 148, 56, 168 Annotation: Subtype: Link Rect: 81, 102, 150, 110 Annotation: Subtype: Link Rect: 372, 376, 471, 385 Annotation: Subtype: Link Rect: 552, 338, 316, 357 Annotation: Subtype: Link Rect: 459, 310, 538, 319 Annotation: Subtype: Link Rect: 345, 272, 424, 281 Annotation: Subtype: Link Rect: 341, 244, 419, 252 Annotation: Subtype: Link Rect: 341, 207, 418, 215 Annotation: Subtype: Link Rect: 341, 168, 423, 177 Annotation: Subtype: Link Rect: 338, 130, 429, 139 Annotation: Subtype: Link Rect: 338, 92, 430, 101 Annotation: Subtype: Link Rect: 43, 28, 109, 37 Annotation: Subtype: Link Rect: 112, 28, 172, 36 Annotation: Subtype: Link Rect: 420, 28, 551, 37 Page: Label: 11 Sequence: 11 Annotations: Annotation: Subtype: Link Rect: 112, 687, 192, 697 Annotation: Subtype: Link Rect: 129, 650, 231, 659 Annotation: Subtype: Link Rect: 108, 604, 193, 611 Annotation: Subtype: Link Rect: 81, 564, 185, 574 Annotation: Subtype: Link Rect: 122, 528, 222, 536 Annotation: Subtype: Link Rect: 81, 489, 172, 498 Annotation: Subtype: Link Rect: 174, 451, 273, 460 Annotation: Subtype: Link Rect: 147, 414, 228, 422 Annotation: Subtype: Link Rect: 292, 365, 56, 385 Annotation: Subtype: Link Rect: 292, 327, 56, 347 Annotation: Subtype: Link Rect: 146, 309, 291, 318 Annotation: Subtype: Link Rect: 57, 300, 226, 309 Annotation: Subtype: Link Rect: 126, 272, 207, 280 Annotation: Subtype: Link Rect: 430, 699, 551, 706 Annotation: Subtype: Link Rect: 428, 670, 499, 678 Annotation: Subtype: Link Rect: 341, 632, 420, 640 Annotation: Subtype: Link Rect: 368, 594, 468, 602 Annotation: Subtype: Link Rect: 461, 566, 537, 573 Annotation: Subtype: Link Rect: 341, 518, 440, 526 Annotation: Subtype: Link Rect: 422, 320, 448, 327 Annotation: Subtype: Link Rect: 448, 320, 480, 327 Annotation: Subtype: Link Rect: 479, 320, 515, 327 Annotation: Subtype: Link Rect: 514, 320, 537, 327 Annotation: Subtype: Link Rect: 552, 308, 303, 328 Annotation: Subtype: Link Rect: 43, 29, 109, 38 Annotation: Subtype: Link Rect: 112, 29, 172, 37 Annotation: Subtype: Link Rect: 420, 29, 551, 38 Checksum: b0111de5 Type: CRC32 Checksum: c50e900405fbdd1247c34af7b7d6ce48 Type: MD5 Checksum: 52e49506ade79d30dfbbb18b122b38c985232695 Type: SHA-1 Checksum: 4444c4df71762233d2b39dc2017d36b7bd725bab2b39e42e875e62ddd9b19b71 Type: SHA-256